Compare Wipro Limited (WIT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wipro Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Wipro Limited trades at $1.69 (market cap $17.95B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Wipro Limited pays a 5.01% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wipro Limited nearer its low. Which is the better fit depends on your goals.
| WIT | XBI | |
|---|---|---|
Market Cap | $17.95B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $3.06 | $169.55 |
52-Week Low | $1.68 | $93.43 |
Enterprise Value | $16.02B | — |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIT trades at $1.73, down 4.42% today, with bearish technical signals and mixed earnings performance. Recent quarters show earnings misses against expectations, though the company maintains strong profitability with 13.92% net margin and 16.09% ROE. Positive business developments include renewed partnerships with ABB and Databricks to enhance digital and AI services.
The outlook is cautious due to earnings volatility and bearish analyst sentiment, with only 19% buy ratings. Risks include competitive pressures and macroeconomic uncertainty affecting tech spending. The stock's valuation appears reasonable with P/E of 12.98, but investor confidence hinges on improved earnings consistency and margin stability.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
